
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals. Which of the following statements is true?
This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals.
Which of the following statements is true?